a Department of Pharmaceutical Chemistry , Geetanjali College of Pharmacy , Udaipur 313001 , India.
b Department of Pharmaceutical Chemistry, Bhupal Nobles' College of Pharmacy , Bhupal Nobles' University , Udaipur 313001 , India.
J Biomol Struct Dyn. 2018 May;36(7):1691-1712. doi: 10.1080/07391102.2017.1332688. Epub 2017 Jun 12.
Despite the various research efforts toward the treatment of stress-related disorders, the drug has not yet launched last 20 years. Corticotropin releasing factor-1 receptor antagonists have been point of great interest in stress-related disorders. In the present study, we have selected benzazole scaffold-based compounds as corticotropin releasing factor-1 antagonists and performed 2D and 3D QSAR studies to identify the structural features to elucidating the binding mechanism prediction. The best 2D QSAR model was obtained through multiple linear regression method with r value of .7390, q value of .5136 and pred_r (predicted square correlation coefficient) value of .88. The contribution of 2D descriptor, T_2_C_1 was 60% (negative contribution) and 4pathClusterCount was 40.24% (positive contribution) in enhancing the activity. Also 3D QSAR model was statistically significant with q value of .9419 and q_se (standard error of internal validation) value of .19. Statistical parameters results prove the robustness and significance of both models. Further, molecular docking and pharmacokinetic analysis was performed to explore the scope of investigation. Docking results revealed that the all benzazole compounds show hydrogen bonding with residue Asn283 and having same hydrophobic pocket (Phe286, Leu213, Ile290, Leu287, Phe207, Arg165, Leu323, Tyr327, Phe284, and Met206). Compound B14 has higher activity compare to reference molecules. Most of the compounds were found within acceptable range for pharmacokinetic parameters. This work provides the extremely useful leads for structural substituents essential for benzimidazole moiety to exhibit antagonistic activity against corticotropin releasing factor-1 receptors.
尽管在治疗与压力相关的疾病方面进行了各种研究努力,但这种药物在过去 20 年中尚未推出。促肾上腺皮质素释放因子-1 受体拮抗剂一直是与压力相关的疾病的研究重点。在本研究中,我们选择了苯并唑骨架化合物作为促肾上腺皮质素释放因子-1 拮抗剂,并进行了 2D 和 3D QSAR 研究,以确定阐明结合机制预测的结构特征。通过多元线性回归方法获得了最佳的 2D QSAR 模型,r 值为.7390,q 值为.5136,pred_r(预测平方相关系数)值为.88。2D 描述符 T_2_C_1 的贡献为 60%(负贡献),4pathClusterCount 的贡献为 40.24%(正贡献),从而增强了活性。此外,3D QSAR 模型在统计学上也是显著的,q 值为.9419,q_se(内部验证的标准误差)值为.19。统计参数结果证明了两个模型的稳健性和显著性。此外,还进行了分子对接和药代动力学分析,以探索研究范围。对接结果表明,所有苯并唑化合物均与残基 Asn283 形成氢键,并且具有相同的疏水性口袋(Phe286、Leu213、Ile290、Leu287、Phe207、Arg165、Leu323、Tyr327、Phe284 和 Met206)。化合物 B14 的活性比参考分子更高。大多数化合物的药代动力学参数都在可接受范围内。这项工作为苯并咪唑部分的结构取代基提供了极其有用的线索,这些取代基对于表现出对抗促肾上腺皮质素释放因子-1 受体的拮抗活性至关重要。